Most recently, the novel PARP inhibitor olaparib is indicated for treating advanced ovarian cancer patients who have mutations in BRCA1 or BRCA2 (Munroe and Kolesar, 2016) and also the identification of KDR alteration as a novel predictive biomarker of exceptional response to low dose regorafenib reported by Loaiza-Bonilla et al. (2016) in patients with advanced CRC. The gene discussed is KDR; the disease is ovarian carcinoma.